Cellular therapy, as a part of regenerative medicine, implies to the treatment of human disorders with cells as a medical product, so called – “living drugs”. Usually such therapy is applied when other alternative efficient pharmacological therapies are not available. Stem cells of different origin: 1) tissue specific e.g. hematopethic, epithelial, neuronal, limbal; 2) mesenchymal stem cells (MSC) harvested from variety of tissues; 3) pluripotent stem cells: embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) – serve as a source of cells for regenerative medicine application, depending upon disease and application requirements. Currently MSC are the type of stem cells that are most frequently used in registered regenerative medicine clinical trials. In this paper we provide the information on the application of cell therapy in orthopedics, hematology, ophthalmology, dermatology, gastrology and neurology. The influence of origin of MSCs and iPSCs on their mode of action as therapeutic, regenerative agents are discussed. Advantages and disadvantages of application of different cell types for cell therapy are underlined. Last, but not least current low regulations in Poland and requirements of European regulatory bodies for cell therapy are pointed out and discussed.